Stay ahead of the latest advances in the fast paced world of cancer antibodies

16th & 17th November 2011
Etc. Venues Paddington, 57 North Wharf Road, London

Why TAC 2011?

Gain insights into recent trends in antibody therapeutics for cancer: antibodies to watch in 2011 and the future

Join in the expert discussion about what biosimilars will mean for the pharma industry

Receive practical advice about taking antibodies from concept to reality with instructive case studies highlighting successful new antibodies in development

Examine how to capture the potential of personalised antibody therapies for cancer

Assess the benefits of bispecific, trifunctional, radiolabelled antibodies and antibody-drug conjugates in the treatment of cancer

Network and exchange ideas with the leading international experts

CALL JACKIE TO BOOK ON +44 (0) 20 7501 6762
Wednesday 16th November

08.00  Registration & refreshments
08.55  Welcome & introduction

HOT TOPICS IN ANTIBODY DEVELOPMENT

09.00  Recent trends in monoclonal antibody therapeutics for cancer
- Metrics for anti-cancer antibody development: time frames and success rates
- Near-term prospects: antibodies to watch in 2011
- Long-term prospects: new formats, new approaches
Dr Janice Reichert, Tufts Centre for the Study of Drug Development, Tufts University Medical School

09.40  Emergence of biosimilars: what will it mean for the industry?
- How similar is “biosimilar”?
- Can biosimilars be interchangeable?
- How will biosimilars impact on patient access?
- Could biobetters offer enhanced patient care?
Dr Cecil Nick, PAREXEL Consulting

10.20  Discussion
10.30  Refreshments and exhibition viewing

ANTIBODY DEVELOPMENT: FROM TARGETS TO PRODUCTION

11.00  Circulating tumour cells as predictive biomarkers
Dr Michael Malone, Clinical Biomarker Specialist, AstraZeneca

11.30  Tissue factor targets for treatment of solid tumours: development of drug-conjugated monoclonal antibodies
- Development and characterisation of antibodies against Tissue Factor (TF)
- Evaluate drug-conjugated antibodies for in vitro and in vivo efficacy against TF expressing cell lines
Dr David Satijn, Genmab

12.00  Challenges of clinical translation and application of biomarkers
To be confirmed

12.30  Discussion
12.45  Networking lunch
13.45  Antibody drug discovery: optimisation of sequence and format
- Screening and selection of antibodies targeting cancer antigens
- Choosing optimal antibody format based on mechanism-of-action
- Finding a compromise between antibody potency and biophysical properties
Graham Craggs, UCB

14.15  Modifying antibody structure to enhance specificity
- Fc polymorphisms of cancer patients show the importance of MAb-Fc interactions in treatment of disease
- MAb Fc engineering has matured and several Fc amino acid and glycosylation variations are available for incorporation into anti-tumor MAbs to improve efficacy in the clinic
Dr William Strohl, Johnson & Johnson

14.45  Discussion
14.55  Refreshments and exhibition viewing

CASE STUDIES: NOVEL ANTIBODIES IN DEVELOPMENT

15.20  RECRUIT-TandAbs: engaging immune cells to kill tumor cells
- TandAbs are tetravalent bispecific homodimers comprised only of antibody variable domains
- TandAbs combine specificities for targeting tumor cells with domains for binding either CD3 or CD16A (FcgammaRIIIA) on T- or NK cells, respectively
- Effector cells cross-linked with TandAbs become activated and subsequently induce the lysis of the targeted tumor cells
- The first TandAb has recently entered into clinical studies for the treatment of Hodgkin’s lymphoma
Professor Melvyn Little, Affimed Therapeutics AG

15.50  Glycolipids as targets for therapeutic anti-tumour monoclonal antibodies
- We have developed a platform for the generation of a novel class of tumour targeting Mabs; the properties of which will be described
- Two targeting colorectal cancer have been licensed, by Kyowa Hakko/Arana, and one is due to enter the clinic in late 2011
- More recently we have successfully developed new glycolpid Mabs: 10 targeting ovarian cancer, 3 targeting gastric cancer and 3 targeting pancreatic cancer, which will soon be entering phase I clinical trials
Professor Lindy Durrant, University of Nottingham & Scancell

16.20  Case example 3
Dr Madhusudan V. Peshwa, Executive Vice-President, Cellular Therapies, MaxCyte Inc

16.50  Discussion
17.05  Networking drinks
Thursday 17th November

08.30 Registration & refreshments

PRACTICAL CONSIDERATIONS

09.00 Forging successful relationships between academia, biotech and pharma industries
- Clinical Development Partnership (CDP) programme
- Innovative ways to progress promising cancer drug candidates
- A CDP case study
Dr Victoria John, Cancer Research UK

09.30 Optimising clinical trials: patient selection, evaluation of endpoints and progression into next phase
- Challenges and opportunities in developing novel targeted cancer therapies
- Pre-clinical strategies to guide patient selection for therapy
- Role of biomarkers in drug development
Professor Jeff Evans, University of Glasgow

10.00 Safety and toxicity testing of therapeutic antibodies
- General preclinical safety considerations for mAbs
- Translational PK/PD in support of early clinical trials
- Alternative preclinical strategies for highly species-selective mAb based therapeutics in oncology
Dr Lolke de Haan, MedImmune

10.30 Challenges in licensing, marketing and commercialisation
Dr Razmic Gregorian, Simon-Kucher & Partners

11.00 Discussion

11.15 Refreshments and exhibition viewing

PERSONALISING ANTIBODY THERAPIES

11.45 Capturing the potential of personalised antibody therapies
To be confirmed

12.15 Polyclonal antibodies and personalised cancer therapies
- Polyclonal antibodies and personalised cancer vaccines
- Passive vs active immunisation in cancer
- Role of peptide antibodies in cancer vaccines
- Advantages and limitations of personalised cancer vaccines
- Future prospects of polyclonal antibodies for personalised therapy of cancer
Professor KK Jain, Jain Pharmabiotech

12.45 Improving patient access to targeted therapy
- Drugs are available to NHS patients so long as they are effective and satisfy current cost-effectiveness assessments

13.15 Discussion

13.30 Networking lunch

NEW TRENDS IN ANTIBODY DEVELOPMENT

14.20 Trifunctional antibodies: combining passive and active immunotherapy
- The trifunctional antibody catumaxomab is the first approved multispecific antibody worldwide
- Trifunctional antibodies (Triomab) have the capacity to induce long-lasting immunity
- Trifunctional antibodies combine passive immunisation (i.e. direct tumour cell killing) with active immunisation raising a broad immune response going beyond the tumour associated antigen originally targeted by the Triomab
Dr Horst Lindhofer, TRION Pharma

14.50 Radiolabelled antibodies
- Radiolabelled antibodies have shown promising clinical efficacy. In the adjuvant setting, on-going clinical trials show an impressive increase in survival in otherwise unmanageable tumors
- Recombinant antibodies and pretargeting approaches have shown potential in increasing the therapeutic index of radiolabelled antibodies
- New radionuclides, e.g. lutetium-177, will further improve the safety of radioimmunotherapy. Alpha particle and Auger electron emitters offer the theoretical possibility to kill the last isolated tumour cell, which is the ultimate challenge in cancer therapy. Preliminary preclinical and clinical results confirm the feasibility of this approach
Dr Jacques Barbet, University of Nantes

15.20 Antibody-drug conjugates for the treatment of cancer
- ADCs are an exciting new approach to the development of antibody-based cancer therapeutics
- What are the underlying principles for a successful ADC?
- Who are the current players and what technologies are in play?
Dr Robert Lutz, ImmunoGen

15.50 Using bispecific antibodies to overcome cancer cell resistance
- Mode of action of BiTE antibodies
- Clinical proof of concept for BiTE antibody blinatumomab
- Overview of BiTE antibodies targeting other malignancies
Dr Roman Kischel, Micromet AG

16.20 Discussion and closing comments

16.40 Refreshments and close of conference
## Targeted Antibodies for Cancer 2011

16th & 17th November 2011  
Etc. Venues Paddington, 57 North Wharf Road, London

### Ways to book:

<table>
<thead>
<tr>
<th>Online at</th>
<th>Booking line:</th>
<th>Cheque:</th>
<th>Fax:</th>
<th>Request an invoice</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="http://www.mahealthcareevents.co.uk/TAC2011">www.mahealthcareevents.co.uk/TAC2011</a></td>
<td>+44 (0)207 501 6762</td>
<td>to the address below</td>
<td>+44 (0)207 978 8319</td>
<td></td>
</tr>
</tbody>
</table>

### Your Details:

- **Title (Dr, Mr, Mrs etc)**
- **Forenames**
- **Surname**
- **Job title**
- **Home address**

### Payment Details:

- **I wish to pay by Credit Card**
  - Please debit my □ Visa □ Mastercard □ Maestro □ American Express

  - Card no ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ ▉ █